Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 2:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 3,701 matching trials from the live ClinicalTrials.gov search.
Conditions
Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer, Carcinoma, Non Small Cell Lung, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Cancer
Interventions
PF-08046876, Pembrolizumab, Cisplatin, Carboplatin
Drug · Combination Product
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
21
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 11 more
Conditions
Non Small Cell Lung Carcinoma
Interventions
Fulvestrant and Erlotinib
Drug
Lead sponsor
Lyudmila Bazhenova, M.D.
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
La Jolla, California
Conditions
Lung Cancer
Interventions
bevacizumab, carboplatin, erlotinib hydrochloride, paclitaxel, gene expression analysis, protein expression analysis, proteomic profiling, laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
7
States / cities
Gainesville, Florida • Atlanta, Georgia • Ann Arbor, Michigan + 2 more
Conditions
Lung Cancer
Interventions
chromogenic in situ hybridization, gene expression analysis, mutation analysis, polymerase chain reaction, polymorphism analysis, fluorescent antibody technique, immunohistochemistry staining method, laboratory biomarker analysis, matrix-assisted laser desorption/ionization time of flight mass spectrometry, study of socioeconomic and demographic variables, study of high risk factors
Genetic · Other · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
981 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
405
States / cities
Anchorage, Alaska • Tucson, Arizona • Fort Smith, Arkansas + 279 more
Conditions
Lung Cancer, Perioperative/Postoperative Complications, Pulmonary Complications, Tobacco Use Disorder
Interventions
exercise intervention, smoking cessation intervention, counseling intervention, educational intervention, conventional surgery, pulmonary complications management/prevention
Behavioral · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 120 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Advanced Solid Tumors
Interventions
OSI-906
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Non-Small Cell Lung Cancer
Interventions
Tepotinib, Ivonescimab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
tipifarnib, cisplatin, gemcitabine hydrochloride, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Non-Small Cell Lung Cancer
Interventions
Thoracic Reirradiation Registry
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Conditions
Lung Cancer
Interventions
temozolomide
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Capmatinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
13
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 10 more
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Cetrelimab, Amivantamab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Duarte, California • Irvine, California • Los Alamitos, California + 3 more
Conditions
Male Breast Carcinoma, Prostate Adenocarcinoma, Recurrent Breast Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Prostate Carcinoma, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Prostate Cancer
Interventions
Stereotactic Body Radiation Therapy (SBRT)
Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
74
States / cities
Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 66 more
Conditions
Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
Interventions
paclitaxel, cisplatin, chest radiotherapy
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Lung Cancer (NSCLC)
Interventions
JBI-802, Pembrolizumab
Drug
Lead sponsor
The Christ Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Non-Small Cell Lung Cancer
Interventions
Alectinib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
45
States / cities
Bimingham, Alabama • Daphne, Alabama • Mobile, Alabama + 35 more
Conditions
Non-small Cell Lung Cancer
Interventions
Atezolizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Brick, New Jersey • Massillon, Ohio • Medford, Oregon + 1 more
Conditions
Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung
Interventions
Adagrasib
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Santa Rosa, California • Kansas City, Missouri • Durham, North Carolina + 1 more
Conditions
Nonsquamous Non-small Cell Lung Cancer
Interventions
Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed, Lenvatinib, Placebo matching lenvatinib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
761 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
17
States / cities
Mountain View, California • New Haven, Connecticut • Fort Lauderdale, Florida + 13 more
Conditions
Lung Cancer, Non-Small Cell
Interventions
pazopanib, paclitaxel
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Chicago, Illinois • Columbus, Ohio
Conditions
Non-small Cell Lung Cancer (NSCLC) With Brain Metastases
Interventions
GRN1005
Drug
Lead sponsor
Angiochem Inc
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
9
States / cities
La Jolla, California • Aurora, Colorado • Tampa, Florida + 6 more
Conditions
Non Small Cell Lung Cancer, Non-small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
7
States / cities
Atlanta, Georgia • Urbana, Illinois • St Louis, Missouri + 4 more
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
temsirolimus, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Lung Cancer
Interventions
accelerated conformational radiotherapy
Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
20
States / cities
Fort Lauderdale, Florida • Hollywood, Florida • Jupiter, Florida + 15 more